Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4260 (MIR4260) is a short (~20-24 nucleotides) non-coding RNA classified as a microRNA that regulates gene expression in multicellular organisms at the post-transcriptional level by affecting mRNA stability and translation[1][3]. MIR4260 is transcribed by RNA polymerase II as part of a primary transcript, processed through the canonical microRNA biogenesis pathway, and loaded into the RNA-induced silencing complex (RISC) where it exerts its gene-silencing activities, typically causing translational repression or degradation of its target mRNAs[1][2][3]. MIR4260 may be involved in diseases such as severe junctional epidermolysis bullosa, but its precise biological functions and therapeutic relevance remain incompletely characterized[1]. As with other microRNAs, it may partake in the regulation of diverse cell biological processes, but there is currently no evidence to support it being a direct therapeutic target, and no drugs or specific biomarkers are established for this molecule[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 4260 (MIR4260).